The FDA has approved NARCAN® Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. The 2mg dose is approved for use in opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.
This approval comes just over one year after the FDA approved the first-of-its-kind, ready-to-use, needle-free version of naloxone, NARCAN® Nasal Spray 4mg, which has been commercially available since February 2016 following expedited FDA review and approval.
NARCAN® Nasal Spray 2mg and 4mg are concentrated naloxone nasal sprays providing ready-to-use emergency treatments of opioid overdose, including prescription opioid painkiller-, fentanyl-, carfentanil- and heroin-related overdose.